Expression of USP22 and the chromosomal passenger complex is an indicator of malignant progression in oral squamous cell carcinoma.
aurora-B
oral squamous cell carcinoma
survivin
ubiquitin-specific protease 22
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
12
05
2016
accepted:
03
10
2018
entrez:
25
1
2019
pubmed:
25
1
2019
medline:
25
1
2019
Statut:
ppublish
Résumé
Oral cancer is a common cancer of the head and neck. Oral squamous cell carcinoma (OSCC) represents almost 90% of the total cases of head and neck cancer. Ubiquitin-specific protease 22 (USP22) is a deubiquitinating hydrolase, and it is highly expressed in various types of cancer, which also typically have a poor prognosis. Aurora-B and Survivin, which belong to the chromosomal passenger complex, are also highly expressed in a number of types of cancer. In the present study, USP22 expression and its associations with Aurora-B and Survivin, and the clinicopathological features in OSCC were explored. USP22 is highly expressed in OSCC. Overexpression of USP22 is associated with lymph node metastasis and histological grade (P<0.01). Additionally, the expression of USP22 was positively associated with Aurora-B (P<0.01), Survivin (P<0.01), and Ki-67 (P<0.01). Furthermore, USP22 small interfering RNA inhibited cell growth and reduced the expression levels of Aurora-B, Survivin and Cyclin B, together with the upregulation of cyclin-dependent kinase inhibitor 1A (p21). These data suggest that USP22, Aurora-B and Survivin promote the OSCC development and may represent novel targets for OSCC diagnosis and treatment in the future.
Identifiants
pubmed: 30675271
doi: 10.3892/ol.2018.9837
pii: OL-0-0-9837
pmc: PMC6341666
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2040-2046Références
Nat Rev Cancer. 2003 Jan;3(1):46-54
pubmed: 12509766
Curr Opin Cell Biol. 2004 Dec;16(6):708-12
pubmed: 15530785
Biochim Biophys Acta. 2004 Nov 29;1695(1-3):189-207
pubmed: 15571815
Mol Cell Biol. 2005 Jun;25(12):4977-92
pubmed: 15923616
J Clin Invest. 2005 Jun;115(6):1503-21
pubmed: 15931389
Hum Pathol. 2005 Dec;36(12):1281-8
pubmed: 16311121
Science. 2005 Dec 2;310(5753):1499-504
pubmed: 16322459
Gene Expr Patterns. 2006 Mar;6(3):277-84
pubmed: 16378762
Virchows Arch. 2007 Mar;450(3):297-302
pubmed: 17235564
Mol Cell. 2008 Jan 18;29(1):92-101
pubmed: 18206972
Mol Cell. 2008 Jan 18;29(1):102-11
pubmed: 18206973
Cell Cycle. 2008 Jun 1;7(11):1522-4
pubmed: 18469533
Oncol Rep. 2009 Sep;22(3):557-62
pubmed: 19639203
J Cell Biol. 2009 Dec 14;187(6):791-800
pubmed: 19995937
Oral Oncol. 2010 Apr;46(4):263-70
pubmed: 20138567
Mol Cell Biochem. 2011 Jan;346(1-2):11-21
pubmed: 20824490
J Surg Oncol. 2011 Mar 1;103(3):283-9
pubmed: 21337558
Exp Cell Res. 2012 Jul 15;318(12):1407-20
pubmed: 22472345
Oncol Lett. 2012 May;3(5):1109-1114
pubmed: 22783401
Nat Rev Mol Cell Biol. 2012 Dec;13(12):789-803
pubmed: 23175282
PLoS One. 2013;8(2):e55710
pubmed: 23405201
Oncol Rep. 2013 May;29(5):1701-6
pubmed: 23467634
World J Clin Oncol. 2014 May 10;5(2):114-24
pubmed: 24829858
Gene. 2015 Nov 1;572(1):49-56
pubmed: 26143114
Int J Oncol. 2015 Dec;47(6):2208-16
pubmed: 26497847
Front Physiol. 2018 Oct 25;9:1510
pubmed: 30410451